BIP Wealth LLC Buys New Position in Becton, Dickinson and Company (NYSE:BDX)

BIP Wealth LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 925 shares of the medical instruments supplier’s stock, valued at approximately $223,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. WR Wealth Planners LLC grew its stake in Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the period. Clear Creek Financial Management LLC grew its position in shares of Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after purchasing an additional 44 shares during the period. Sound Income Strategies LLC increased its stake in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Central Pacific Bank Trust Division lifted its position in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 45 shares during the period. Finally, Tompkins Financial Corp boosted its stake in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Price Performance

BDX opened at $222.73 on Wednesday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The company has a 50 day moving average of $235.78 and a two-hundred day moving average of $234.80. The company has a market cap of $64.38 billion, a P/E ratio of 37.50, a P/E/G ratio of 1.68 and a beta of 0.43. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the company earned $3.42 EPS. The firm’s revenue was up 6.9% on a year-over-year basis. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a dividend of $1.04 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.87%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.